Raising Capital & Financing

Cybin is a clinical-stage biopharmaceutical company on a mission to create safe and effective psychedelic-based therapeutics to address the large unmet need for new and innovative treatment options for people who suffer from mental health conditions. Cybin’s goal of revolutionizing mental healthcare is supported by a network of world-class partners and internationally recognized scientists aimed at progressing proprietary drug discovery platforms, innovative drug delivery systems, and novel formulation approaches and treatment regimens. The Company is currently developing CYB003, a proprietary deuterated psilocybin analog for the treatment of major depressive disorder and CYB004, a proprietary deuterated DMT molecule for generalized anxiety disorder and has a research pipeline of investigational psychedelic-based compounds. Headquartered in Canada and founded in 2019, Cybin is operational in Canada, the United States, the United Kingdom, the Netherlands and Ireland.

Satellos is a publicly traded biotechnology company dedicated to developing life-improving medicines to treat degenerative muscle diseases. Satellos has incorporated breakthrough research in muscle stem cell polarity into a proprietary discovery platform, called MyoReGenXTM, to identify degenerative muscle diseases where deficits in this process affect muscle regeneration and are amenable to therapeutic intervention. With this platform, Satellos is building a pipeline of novel therapeutics to correct muscle stem cell polarity and promote the body's innate muscle repair and regeneration process. The Company's lead program is an oral, small molecule drug candidate in development as a disease-modifying treatment for Duchenne muscular dystrophy. Satellos is headquartered in Toronto, Ontario.

BetterLife Pharma Inc. is an emerging biotechnology company primarily focused on developing and commercializing two compounds, BETR-001 and BETR-002, to treat neuro-psychiatric and neurological disorders.

BETR-001, which is in preclinical and IND-enabling studies, is a non-hallucinogenic and non-controlled LSD derivative in development and it is unique in that it is unregulated and therefore can be self-administered. BetterLife’s synthesis patent for BETR-001 eliminates regulatory hurdles and its pending patent, for composition and method of use, covers treatment of major depressive disorder, anxiety disorder and neuropathic pain and other neuro-psychiatric and neurological disorders.

BETR-002, which is in preclinical and IND-enabling studies, is based on honokiol, the active anxiolytic ingredient of magnolia bark. BetterLife’s pending method of use and formulations patent covers treatment of anxiety related disorders including benzodiazepine dependency.

BetterLife also owns a drug candidate for the treatment of viral infections such as COVID-19 and is in the process of seeking strategic alternatives for further development.

FORUS Therapeutics is a Canadian biopharmaceutical company dedicated to advancing differentiated, novel medicines for hematologic malignancies and other forms of cancer. Our mission is to bring solutions to cancer patients, caregivers, physicians and our partners by accelerating unique and important treatments that meaningfully enhance life.

CareRx is Canada's leading provider of pharmacy services to seniors living communities. We serve over 93,000 residents in over 1,600 seniors and other congregate care communities (long-term care homes, retirement homes, assisted living facilities, and group homes). We are a national organization with a large network of pharmacy fulfillment centres strategically located across the country. This allows us to deliver medications in a timely and cost-effective manner and quickly respond to routine changes in medication management. We use best-in-class technology that automates the preparation and verification of multi-dose compliance packaging of medication, providing the highest levels of safety and adherence for individuals with complex medication regimes. We take an active role in working with our home operator partners to promote resident health, staff education, and medication system quality and efficiency.

Satellos is a biotechnology company dedicated to developing life-changing medicines to treat degenerative muscle conditions. Our scientists discovered what we believe to be a previously unrecognized root cause of skeletal muscle degeneration. One which has the potential to transform how muscle disorders are treated.

Satellos' lead program is focused on developing an oral therapeutic drug (i.e., a pill) intended to correct muscle stem cell polarity and restore the body's innate muscle repair and regeneration process. We believe our unique therapeutic approach represents a potential disease modifying treatment for Duchenne and other dystrophies, offering new hope to patients. To expand our programs to other degenerative muscle conditions or disorders, Satellos has created a proprietary discovery platform, MyoReGenX™, which we utilize to identify disease situations where deficits in muscle stem cell polarity and regeneration occur and are amenable to therapeutic treatment.

Medicenna is a clinical-stage immunotherapy company focused on the development of novel, highly selective versions of IL-2, IL-4 and IL-13 Superkines and Empowered Superkines.

Appili Therapeutics is an infectious disease biopharmaceutical company that is purposefully built, portfolio-driven, and people-focused to fulfill its mission of solving life-threatening infections. By systematically identifying urgent infections with unmet needs, Appili’s goal is to strategically develop a pipeline of novel therapies to prevent deaths and improve lives. The Company is currently advancing a diverse range of anti-infectives, including a broad-spectrum antifungal, a vaccine candidate to eliminate a serious biological weapon threat, a topical antiparasitic product for the treatment of a disfiguring disease, and two novel antibiotic programs. Led by a proven management team, Appili is at the epicenter of the global fight against infection.

Virica optimizes the manufacturing of viral medicines which allows developers to economically deploy their products at scale. Virica’s Viral Sensitizer (VSE™) platform reduces production inefficiencies caused by innate anti-viral defenses in manufacturing cells. Customizable VSE cocktails substantially increase manufacturing yields and reduce the cost of goods for a range of products, including vaccines, cell and gene therapies, and anticancer therapies.

Newtopia is a tech-enabled habit change provider focused on disease prevention and reducing the cost of care for health insurers. As a provider of whole person care, we prevent, reverse, and slow the progression of chronic disease while enriching mental health, resilience and overall human performance. Newtopia's programs leverage genetic, social, and behavioural insights to create individualized prevention programs with a focus on type 2 diabetes, heart disease, stroke and weight. With a person-centered approach that combines virtual care, digital tools, connected devices and actionable data science, Newtopia delivers sustainable clinical and financial outcomes. Newtopia serves some of the largest nationwide employers and health plans and is currently listed on the Toronto Stock Exchange and quoted on the OTC Venture Market in the United States (TSXV: NEWU) (OTCQB: NEWUF).

BELLUS Health Inc. is a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of refractory chronic cough (“RCC”) and other hypersensitization-related disorders. The Company's product candidate, BLU-5937, is being developed for the treatment of adults with RCC.

Appili Therapeutics Inc. (TSX: APLI) (the “Company” or “Appili”) announced the closing of its previously announced public offering (the “Offering”) of units (the “Units”). The Offering was made pursuant to an agency agreement entered into with a syndicate of agents led by Bloom Burton Securities Inc. (the “Lead Agent”) and including iA Private Wealth Inc., Leede Jones Gable Inc., Research Capital Corporation, and Richardson Wealth Limited (collectively with the Lead Agent, the “Agents”) and the Company.

Pursuant to the Offering, the Company issued a total of 8,434,000 Units at a price of $0.83 per Unit for aggregate gross proceeds of $7,000,220. Each Unit is comprised of one Class A common share of the Company (a “Common Share”) and one-half of one Common Share purchase warrant of the Company (each whole Common Share purchase warrant, a “Warrant”). Each Warrant entitles the holder thereof to acquire one Common Share (a “Warrant Share”) at an exercise price of $1.10 per Warrant Share until October 14, 2024.

Greenbrook TMS Inc. (TSX: GTMS) (NASDAQ: GBNH) (“Greenbrook” or the “Company”), a leading provider of Transcranial Magnetic Stimulation (“TMS”) therapy in the United States, is pleased to announce the closing of its previously-announced public offering (the “Offering”). The Offering was made pursuant to an underwriting agreement entered into among Stifel GMP, Bloom Burton Securities Inc. and Lake Street Capital Markets, LLC (collectively, the “Underwriters”).

Pursuant to the Offering, the Company issued a total of 1,707,750 common shares of the Company (the “Common Shares”) at a price of US$7.75 per Common Share for gross proceeds of approximately US$13.2 million, including 222,750 Common Shares issued pursuant to the full exercise of the Underwriters’ over-allotment option. The Company intends to use the net proceeds from the Offering to fund its previously-announced acquisition of Achieve TMS East, LLC and Achieve TMS Central, LLC and for working capital and general corporate purposes.

The Common Shares were qualified for sale by way of a prospectus supplement (the “Prospectus Supplement”) to the Company’s short form base shelf prospectus dated July 22, 2021 (the “Base Shelf Prospectus”) in the United States and Canada. The Prospectus Supplement was also filed with the U.S. Securities and Exchange Commission (the “SEC”) to the Base Shelf Prospectus as part of the Company’s effective registration statement on Form F-10 previously filed under the U.S./Canada multi-jurisdictional disclosure system.

Clarus Securities Inc. and Desjardins Securities Inc. served as independent financial advisors to the Company in connection with the Offering.

Grey Wolf Animal Health is a specialty animal health company focused on improving the lives and well-being of vets and pets in Canada. Founded in 2015 by Dr. Ian Sandler, our mission is to identify and bring to market products, solutions and services that meet the underserved needs of vets, pets and clinics across Canada.

MISSISSAUGA, Ontario, May 19, 2021 (GLOBE NEWSWIRE) -- Microbix Biosystems Inc. (TSX: MBX, OTCQB: MBXBF, Microbix®), a life sciences innovator and exporter, announces it has closed its previously-announced bought-deal public offering (the “Offering”) and concurrent private placement (the “Placement”).

The co-lead bookrunners and underwriters of the Offering, iA Private Wealth Inc. and Bloom Burton Securities Inc. (the “Underwriters”), have purchased the full Offering, including all of the 15% overallotment option, for a total of 9,583,334 units (“Units”), at a price of $0.60 per Unit for aggregate gross proceeds of $5,750,000. The Company also closed its concurrent Placement of 1,916,666 Units for gross proceeds of $1,150,000, also upsized by 15% from the previously announced $1,000,000.

iCo Therapeutics Inc. (TSXV: ICO) (OTC: ICOTF) ("iCo" or the "Company") is pleased to announce that it has closed its previously announced private placement (the "Financing") in connection with its proposed business combination with Satellos Bioscience Inc. ("Satellos") by way of a plan of arrangement (the "Arrangement") in accordance with Section 192 of the Canada Business Corporations Act. The completion of the Arrangement will result in the reverse takeover of the Company as defined in the policies of the TSX Venture Exchange ("TSXV") and the resulting entity will continue to operate in the life sciences industry under the name "Satellos Bioscience Inc." (the "Resulting Issuer").

Pursuant to the Financing, the Company issued 85,294,117 subscription receipts (the "Subscription Receipts") at a price of $0.085 per Subscription Receipt for aggregate gross proceeds of approximately C$7.25 million. Each Subscription Receipt will entitle the holder thereof to receive, upon satisfaction of certain escrow release conditions, including without limitation, the completion of the Arrangement, and without payment of additional consideration, one common share of the Resulting Issuer (a "Resulting Issuer Share"). The proceeds from the Financing have been placed in escrow and, upon satisfaction of the escrow release conditions, will be used for research, development, and general corporate expenses of the Resulting Issuer.

The Resulting Issuer Shares issued in connection with the Financing will be subject to a hold period expiring 4 months and one day from the date of issuance in accordance with applicable Canadian securities laws. Additionally, in connection with the Financing, certain Resulting Issuer Shares issued to former shareholders of Satellos pursuant to the Arrangement will be subject to a lock-up agreement.

The Financing was led by Bloom Burton Securities Inc. and includes Richardson Wealth Ltd.

TORONTO, March 17, 2021 (GLOBE NEWSWIRE) -- Field Trip Health Ltd. (CSE: FTRP; FTRP.WT; OTCQX: FTRPF) ("Field Trip"), a leader in the development and delivery of psychedelic therapies, is pleased to announce that it has closed the bought deal short form prospectus offering previously announced on February 25 and 26, 2021, including the full exercise of the underwriters’ over-allotment option (the "Offering"). In connection with the Offering, Field Trip issued 14,661,499 common shares, (“Common Shares”) at a price of C$6.50 per Common Share, for aggregate gross proceeds of $95 million.

TORONTO--(BUSINESS WIRE)--Antibe Therapeutics Inc. ("Antibe" or the "Company") (TSX:ATE) today announced that it has closed its previously announced bought deal public offering of 6,727,500 units (the “Offered Securities”) in the capital of the Company at a price of C$6.00 per Offered Security (the “Offering Price”) for aggregate gross proceeds to the Company of C$40,365,000 (the “Offering”), which includes the full exercise of the over-allotment option by the underwriters.

Each Offered Security consisted of one common share (a “Common Share”) and one-half of one common share purchase warrant (each whole warrant, a “Warrant”). Each Warrant entitles the holder thereof to acquire one Common Share at an exercise price per Common Share of C$7.50 for a period of 36 months from the closing of the Offering.

TORONTO--(BUSINESS WIRE)--Titan Medical Inc. (“Titan” or the “Company”) (TSX: TMD) (Nasdaq: TMDI), a medical device company focused on the design and development of surgical technologies for robotic single access surgery, announced today that it closed its previously announced offering of 8,335,000 units of the Company (“Units”) sold on a “bought deal” basis for gross proceeds of US $20,004,000 (the “Offering”). Bloom Burton Securities Inc. acted as underwriter for the Offering and exercised its over-allotment option in full on the date hereof for an additional 1,250,250 Units and additional gross proceeds to the Company of US $3,000,600. The aggregate gross proceeds to the Company under the Offering were US $23,004,600.

TORONTO, CHICAGO and MONTREAL, Feb. 23, 2021 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals Inc. (“Medexus” or the “Company”) (TSXV:MDP) (Frankfurt: P731) announced today that it has closed its previously announced bought deal public offering of 4,581,689 units (the “Units”) at a price of $7.10 per Unit for total gross proceeds of approximately $32,529,992 (the “Offering”), including 597,611 Units sold pursuant to the exercise in full of the over-allotment option granted to the Underwriters (as defined herein).

The Offering was led by Raymond James Ltd. and Stifel GMP, as co-lead underwriters and joint bookrunners, on behalf of a syndicate of underwriters consisting of Roth Canada, ULC, Bloom Burton Securities Inc. and Mackie Research Capital Corporation (collectively, the “Underwriters”).

VANCOUVER, BC and HOUSTON, March 4, 2021 /PRNewswire/ - ESSA Pharma Inc. ("ESSA", or the "Company") (Nasdaq: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today announced that the underwriters have exercised their option (the "Option") to purchase an additional 724,637 common shares in the capital of the Company (the "Common Shares"), in connection with the Company's recently completed underwritten public offering of 4,830,918 Common Shares, which closed on February 22, 2021 (the "Offering"). On closing of the Option, the Company will have issued 5,555,555 Common Shares pursuant to the Offering for gross proceeds of approximately $150 million.

OTTAWA, ON / Business Wire/– February 16, 2021 – Avivagen Inc. (TSXV:VIV) (“Avivagen” or the “Company”), a life sciences corporation focused on developing and commercializing products for livestock, companion animal and human applications that safely enhance and support immune function, thereby supporting general health and performance, announced today that it closed its previously announced offering of 15,000,000 units of the Company (the “Units”) on a “bought deal” basis, at a price of $0.50 per Unit (the “Offering Price”) for aggregate gross proceeds of $7,500,000 (the “Offering”). Bloom Burton Securities Inc. (the “Underwriter”) acted as underwriter for the Offering.

TORONTO--(BUSINESS WIRE)--Cybin Inc. (NEO:CYBN) (“Cybin” or the “Company”), a biotechnology company focused on progressing psychedelic therapeutics, is pleased to announce that it has closed its previously announced bought deal short form prospectus offering (the “Offering”), including the exercise of the over-allotment option granted to the Underwriters (as defined herein). In connection with the Offering, the Company issued 15,246,000 units of the Company (the “Units”) at a price of CDN$2.25 per Unit (the “Issue Price”) for aggregate gross proceeds of CDN$34,303,500. The Offering was conducted by Canaccord Genuity (the “Lead Underwriter”), as lead underwriter and sole bookrunner, with Stifel Nicolaus Canada Inc., Eight Capital and Bloom Burton Securities Inc. (together with the Lead Underwriter, the “Underwriters”). To date, the Company has raised approximately CDN$88.8 million.

TORONTO--(BUSINESS WIRE)--Titan Medical Inc. (“Titan” or the “Company”) (TSX: TMD) (Nasdaq: TMDI), a medical device company focused on the design and development of surgical technologies for robotic single access surgery, announced today that it closed its previously announced offering of 6,451,613 units of the Company (“Units”) sold on a “bought deal” basis for gross proceeds of approximately US $10,000,000.00 (the “Offering”). Bloom Burton Securities Inc. (the “Underwriter”) acted as underwriter for the Offering and exercised its over-allotment option in full on the date hereof for an additional 967,741 Units and additional gross proceeds to the Company of approximately US $1,500,000. The aggregate gross proceeds to the Company under the Offering were approximately US $11,500,000.

TORONTO, Jan. 05, 2021 (GLOBE NEWSWIRE) -- Field Trip Health Ltd. (“Field Trip” or the “Company”) (CSE: FTRP) (OTCBB: FTRPF), a leader in the development and delivery of psychedelic therapies, is pleased to announce that it has closed its previously announced bought deal short form prospectus offering, including the exercise in full of the underwriters' over-allotment option (the "Offering"). In connection with the Offering, the Company issued 4,448,200 units of the Company (the "Units") at a price of CAD$4.50 per Unit, for aggregate gross proceeds of $20,016,900. The Offering was conducted by Stifel GMP (the “Lead Underwriter”), as lead underwriter and sole bookrunner with Canaccord Genuity Corp., Bloom Burton Securities Inc. and Eight Capital forming the syndicate of underwriters (together with the Lead Underwriter, the “Underwriters”).

TORONTO, Dec. 23, 2020 (GLOBE NEWSWIRE) -- MindBeacon Holdings Inc. (“MindBeacon” or the “Company”) (TSX: MBCN) announced today the successful closing of its previously announced initial public offering (the “Offering”) pursuant to which it and TELUS Corporation, 1930339 Ontario Inc., 2451585 Ontario Inc. and 1964998 Ontario Inc. (the “Selling Shareholders”) sold an aggregate of 9,343,750 common shares at a price of $8.00 per share, for total gross proceeds of $74,750,000. The Offering includes the exercise in full by the Underwriters (as defined below) of their over-allotment option to acquire 1,218,750 additional shares of the Company from the Selling Shareholders. The Company received gross proceeds of $65,000,000 and the Selling Shareholders received gross proceeds of $9,750,000.

BURLINGTON, ON, Dec. 3, 2020 /CNW/ - AceAge Inc. ("AceAge"), a Canadian healthcare technology company with its innovative medication dispenser, Karie, announced that it has closed a CA $5 million Series A financing round led by Longliv Ventures, a member of the CK Hutchison Holdings Group ("CKHH"), with the participation of a fund managed by the Bloom Burton Investment Group ("Bloom Burton"). Dr Dan Eldar, Managing Director at Longliv Ventures, will join the AceAge Board of Directors. Longliv Ventures Fund, a member of CKHH, focuses on consumer-oriented digital health solutions. CKHH, via its retail division AS Watson, operates the world's largest international health and beauty retailer, with over 15,800 stores in 27 markets worldwide.

TORONTO, Oct. 29, 2020 /CNW/ - Newtopia Inc. ("Newtopia" or the "Company") (TSXV: NEWU), a tech-enabled disease prevention company focused on healthy habit change, is pleased to announce that it has closed its previously announced bought deal private placement offering of 7,900,000 units of the Company (the "Units") at a price of $0.95 per Unit (the "Offering Price") for aggregate gross proceeds of $7,505,000 (the "Offering"). The Offering was conducted through a syndicate of underwriters led by Bloom Burton Securities Inc. and included Stifel GMP and INFOR Financial Inc. (collectively, the "Underwriters").

HOUSTON and VANCOUVER, BC, July 31, 2020 /CNW/ - ESSA Pharma Inc. ("ESSA", or the "Company") (Nasdaq: EPIX) (TSX-V: EPI), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today announced the closing of an underwritten public offering of 7,100,000 common shares of the Company at a public offering price of US$6.00 per share, before underwriting discounts, for an aggregate offering of approximately US$42.6 million (the "Offering"). ESSA granted the underwriters a 30-day option to purchase up to an additional 1,065,000 common shares (the "Option"), and the underwriters exercised the Option on July 29, 2020. The proceeds to ESSA from the Offering, including the exercise of the Option, were approximately US$45.0 million after deducting underwriting discounts and commissions (such commission being equal to 6% of the aggregate gross proceeds of the Offering) and other estimated offering expenses. Existing investors participated in the financing along with new investors Pfizer Inc. (NYSE: PFE), Avidity Partners, CAM Capital, Point72, Ridgeback Capital, Sphera Healthcare and Vivo Capital.

Toronto, Ontario--(Newsfile Corp. - June 30, 2020) - Antibe Therapeutics Inc. (TSXV: ATE) ("Antibe" or the "Company") announced that it closed its previously announced bought deal public offering of 62,500,000 units of the Company (the "Units") at a price of $0.40 per Unit (the "Offering Price") plus the exercise in full of the Underwriters' over-allotment option of 9,375,000 units for aggregate gross proceeds of $28,750,000 (the "Offering"). The Offering was made pursuant to an underwriting agreement dated June 15, 2020 with a syndicate of underwriters led by Bloom Burton Securities Inc., together with Echelon Wealth Partners Inc., Paradigm Capital Inc., Raymond James Ltd., Stifel GMP and Industrial Alliance Securities Inc. (collectively, the "Underwriters").

Appili Therapeutics Inc. (TSXV: APLI) (the “Company” or “Appili”) announced the closing of its previously announced public offering (the “Public Offering”) of units (the “Units”). The Public Offering was made pursuant to an agency agreement entered into with a syndicate of agents led by Bloom Burton Securities Inc. (the “Lead Agent”) and including Mackie Research Capital Corporation, Industrial Alliance Securities Inc., Haywood Securities Inc., and Richardson GMP Limited (collectively with the Lead Agent, the “Agents”) and the Company.

TORONTO, ON, May 21, 2020 – Greenbrook TMS Inc. (“Greenbrook” or the “Company”) (TSX: GTMS) is pleased to announce the closing of its previously announced public offering (the “Offering”) of common shares of the Company (the “Offered Shares”). The Offering was made pursuant to an agency agreement (the “Agency Agreement”) entered into among Bloom Burton Securities Inc. and Clarus Securities Inc., as co-lead agents, Canaccord Genuity Corp., Desjardins Securities Inc. and Stifel GMP (collectively, the “Agents”).